Trump announces 100% chip tariff as Apple ups U.S. investment
John Fesko, President and Chief Business Officer at Natera, Inc. (NASDAQ:NTRA), a $19.2 billion market cap company with a GOOD financial health rating according to InvestingPro, sold a total of 1,777 shares of common stock in two transactions, realizing approximately $272,770.
On May 27, 2025, Fesko sold 1,438 shares at a price of $156.8505 per share. Then, on July 21, 2025, he sold 339 shares at $139.29 per share. Following these transactions, Fesko directly owns 153,460 shares of Natera. The company has shown impressive revenue growth of 51.5% over the last twelve months, though InvestingPro analysis indicates the stock is currently trading above its Fair Value.
The sales were executed to cover tax obligations related to the vesting of Restricted Stock Units (RSUs) and were made under a pre-arranged trading plan that complies with Rule 10b5-1(c). With strong liquidity indicated by a current ratio of 3.87 and projected revenue growth of 18% for FY2025, InvestingPro subscribers can access 12 additional key insights about Natera’s financial outlook and valuation metrics through the comprehensive Pro Research Report.
In other recent news, Natera reported impressive first-quarter 2025 earnings, exceeding analysts’ expectations with an earnings per share (EPS) of -$0.50 compared to the forecasted -$0.64. The company also saw a significant revenue increase, reaching $522 million, which represents a 37% growth year-over-year. Additionally, Medicare has expanded its coverage for Natera’s Signatera MRD assay to include a broader range of cancers, following a pan-cancer study presented at the 2025 American Society of Clinical Oncology Annual Meeting.
Analysts from RBC Capital Markets and TD Cowen have expressed positive outlooks on Natera’s performance. RBC Capital maintained an Outperform rating with a price target of $251, citing strong commercial execution and improved profit margins. Similarly, TD Cowen raised the price target to $200, noting a 13% increase in sales, driven by a 5% rise in core sales and 8% from other favorable factors.
Natera’s Signatera product has shown substantial growth, with clinical volumes rising to approximately 17,000 in the first quarter, marking a 52% year-over-year increase. This comes amid concerns about potential volume issues affecting some peers due to weather-related disruptions. Meanwhile, Leerink Partners reiterated its Outperform rating for Natera, maintaining a price target of $220, following developments regarding Medicare coverage for the WGS Signatera assay.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.